Brondfield Max N, Reid Michael J A, Rutishauser Rachel L, Cope Jennifer R, Tang Jevon, Ritter Jana M, Matanock Almea, Ali Ibne, Doernberg Sarah B, Hilts-Horeczko Alexandra, DeMarco Teresa, Klein Liviu, Babik Jennifer M
School of Medicine, University of California San Francisco (UCSF), San Francisco, CA, USA.
Division of Infectious Diseases, UCSF, San Francisco, CA, USA.
Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12661. Epub 2017 Mar 6.
Disseminated acanthamoebiasis is a rare, often fatal, infection most commonly affecting immunocompromised patients. We report a case involving sinuses, skin, and bone in a 60-year-old woman 5 months after heart transplantation. She improved with a combination of flucytosine, fluconazole, miltefosine, and decreased immunosuppression. To our knowledge, this is the first case of successfully treated disseminated acanthamoebiasis in a heart transplant recipient and only the second successful use of miltefosine for this infection among solid organ transplant recipients. Acanthamoeba infection should be considered in transplant recipients with evidence of skin, central nervous system, and sinus infections that are unresponsive to antibiotics. Miltefosine may represent an effective component of a multidrug therapeutic regimen for the treatment of this amoebic infection.
播散性棘阿米巴病是一种罕见的、通常致命的感染,最常影响免疫功能低下的患者。我们报告一例心脏移植术后5个月的60岁女性病例,其鼻窦、皮肤和骨骼均受影响。她通过联合使用氟胞嘧啶、氟康唑、米替福新以及减少免疫抑制得以好转。据我们所知,这是心脏移植受者中首例成功治疗播散性棘阿米巴病的病例,也是实体器官移植受者中米替福新成功用于治疗该感染的第二例。对于有皮肤、中枢神经系统和鼻窦感染证据且对抗生素无反应的移植受者,应考虑棘阿米巴感染。米替福新可能是治疗这种阿米巴感染的多药治疗方案的有效组成部分。